Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 3, 1996, Pages 312-321

  Slayter, Kathryn L ^b   Ludwig, Elizabeth A ^b   Lew, Kim H ^b   Middleton Jr , Elliott ^b   Ferry, James J ^b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HISTAMINE; LEVONORGESTREL; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; ORAL CONTRACEPTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BASOPHIL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; AMERICAS; BIOLOGY; CLINICAL RESEARCH; CLINICAL TRIALS; CONTRACEPTION; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; FAMILY PLANNING; HORMONES; METABOLIC EFFECTS; NEW YORK; NORTH AMERICA; NORTHERN AMERICA; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, COMBINED; ORAL CONTRACEPTIVES, PHASIC; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; STEROID METABOLIC EFFECTS; UNITED STATES;

ADULT; ANTI-INFLAMMATORY AGENTS; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-OVER STUDIES; FEMALE; HISTAMINE; HUMANS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; METHYLPREDNISOLONE; REFERENCE VALUES;

EID: 0029880920     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)80009-9     Document Type: Article

References (39)

1. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-84.
2. Teichman AT. Influence of oral contraceptives on drug therapy. Am J Obstet Gynecol 1990;163:2208-13.
3. Guengerich FP. Metabolism of 17α-ethynylestradiol in humans. Life Sci 1990;47:1981-8.
4. Mackinnon MM, Sutherland E, Simon FR. Effects of ethinyl estradiol on hepatic microsomal proteins and the turnover of cytochrome P-450. J Lab Clin Med 1977;90:1096-106.
5. O'Malley K, Stevenson IH, Crooks J. Impairment of human drug metabolism by oral contraceptive steroids. CLIN PHARMACOL THER 1972;13:552-7.
6. Abernethy DR, Greenblatt DJ, Divoll M, Arendt R, Ochs HR, Shader RI. Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. N Engl J Med 1982;306:791-2.
7. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8.
8. Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol 1982;23:129-34.
9. Mitchell MC, Hanew T, Meredith CG, Schenker S. Effects of oral contraceptive steroids on acetaminophen metabolism and elimination. CLIN PHARMACOL THER 1983;34:48-53.
10. Patwardahan RV, Mitchell MC, Johnson RF, Schenker S. Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines. Hepatology 1983;3:248-53.
11. Meffin PJ, Wing MH, Sallustio BC, Brooks PM. Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol 1984;17:655-64.
12. Legler UF, Benet LZ. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. CLIN PHARMACOL THER 1986;39:425-9.
13. Boekenoogen SJ, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 1983;56:702-9.
14. Mills IH, Schedl HP, Chen PS, Bartter C. The effect of estrogen administration on the metabolism and protein binding of hydrocortisone. J Clin Endocrinol Metab 1960;20:515-28.
15. Legler UF. Lack of impairment of fluocortolone disposition in oral contraceptive users. Eur J Clin Pharmacol 1988;35:101-3.
16. Szefler SJ, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol 1986;30:323-9.
17. Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 1980;66:447-51.
18. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. CLIN PHARMACOL THER 1986;39:654-9.
19. Wald JA, Salazar DE, Cheng H, Jusko WJ. Two-compartment basophil trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm 1991;19:521-36.
20. Fisher LE, Ludwig EA, Jusko WJ. Pharmacoimmunodynamics of methylprednisolone trafficking of helper T lymphocytes. J Pharmacokinet Biopharm 1992;20:319-31.
21. Lew KH, Ludwig EA, Milad MA, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. CLIN PHARMACOL THER 1993;54: 402-14.
22. Ebling WF, Szefler SJ, Jusko WJ. Analysis of cortisol, methylprednisolone and methylprednisolone hemisuccinate: absence of effects of troleandomycin on ester hydrolysis. J Chromatogr 1984;305:271-80.
23. Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983;16:203-16.
24. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. CLIN PHARMACOL THER 1991;49:536-49.
25. Tafurt CA, Sobrevilla LA, Estrada R. Effects of progestin-estrogen combination and progestational contraceptives on pituitary gonadotropins, gonadal steroids, and sex hormone-binding globulin. Fertil Steril 1980;33:261-6.
26. Jusko WJ, Ludwig EA. Corticosteroids. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver, Washington: Applied Therapeutics, 1992:[Chapter 27]1-34.
27. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. CLIN PHARMACOL THER 1993;54:621-9.
28. Ortiz DE, Montellano PR, Kunze KL, Yost GS, Mico BA. Self- catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proc Natl Acad Sci USA 1979;76:746-9.
29. Guengerich FP. Minireview: metabolism of 17α-ethynylestradiol in humans. Life Sci 1990;47:1981-8.
30. Chambers DM, Jefferson GC, Chambers M, Loudon NB. Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids. Br J Clin Pharmacol 1982;13:229-32.
31. Halpert JR, Guengerich FP, Bend JR, Correia MA. Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 1994;125:163-75.
32. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
33. Burke CW. Biologically active cortisol in plasma of oestrogen-treated and normal subjects. Br Med J 1969;2:798-800.
34. Plager JE, Schmidt KG, Staubitz WJ. Increased unbound cortisol in the plasma of estrogen-treated subjects. J Clin Invest 1964;43:1066-72.
35. Spangler AS, Antoniades HN, Sotman SL, Inderbitizin TM. Enhancement of the anti-inflammatory action of hydrocortisone by estrogen. J Clin Endocrinol Metab 1969;29:650-5.
36. Nelson DH, Tanney H, Mestman G, Gieschen VW, Wilson LD. Potentiation of the biological effect of administered cortisol by estrogen treatment. J Clin Endocrinol Metab 19+63;23:261-5.
37. Doe RP, Dickinson P, Zinneman, HH. Elevated non-protein bound cortisol (NPC) in pregnancy, during estrogen administration and in carcinoma of the prostate. J Clin Endocrinol Metab 1969;29: 757-66.
38. Turner BB. Sex difference in glucocorticoid binding in rat pituitary is estrogen dependent. Life Sci 1990;46: 1399-406.
39. Frey BM, Frey FJ. The effect of altered prednisolone kinetics in patients with the nephrotic syndrome and in women taking oral contraceptive steroids on human mixed lymphocyte cultures. J Clin Endocrinol Metab 1985;60:361-9.